Yonsei Med J.  2013 Nov;54(6):1353-1361. 10.3349/ymj.2013.54.6.1353.

Cyclooxygenase-2 Polymorphisms and Susceptibility to Colorectal Cancer: A Meta-Analysis

• Wang J
• Guo X
• Zhang J
• Song J
• Ji M
• Yu S
• Wang J
• Cao Z
• Dong W

• KMID: 1798130
• DOI: http://doi.org/10.3349/ymj.2013.54.6.1353

Abstract

PURPOSE
Four polymorphisms, -765G>C, -1195G>A, 8473T>C, and Val511Ala, in the cyclooxygenase-2 (COX-2) gene were identified to be associated with colorectal cancer (CRC) risk. However, the results are inconsistent. The objective of this meta-analysis was to evaluate the association between these four polymorphisms and the risk of CRC.
MATERIALS AND METHODS
All eligible case-control studies published up to December 2012 on the association between the four polymorphisms of COX-2 and CRC risk were identified by searching PubMed and Web of Science. The CRC risk associated with the four polymorphisms of the COX-2 gene was estimated for each study by odds ratio (OR) together with its 95 % confidence interval (CI), respectively.
RESULTS
A total of 15 case-control studies were included. Overall, no evidence has indicated that the -1195A allele, -765C allele, 8473C allele, and 511Ala allele are associated with susceptibility to CRC (-1195G>A: OR=1.11, 95 % CI: 0.82-1.51, p=0.78; -765G>C: OR=1.08, 95 % CI: 0.96-1.21, p=0.07; 8473T>C: OR=1.03, 95 % CI: 0.89-1.18, p=0.91; Val511Ala: OR=0.71, 95 % CI: 0.46-1.09, p=0.94). However, stratified analysis with ethnicity indicated that individuals with -765GC or GC/CC genotypes had an increased risk of CRC among Asian populations (GC vs. GG: OR=1.05, 95 % CI: 0.87-1.28, p=0.03; GC+CC vs. GG: OR=1.08, 95 % CI: 0.96-1.21, p=0.07).
CONCLUSION
This meta-analysis indicated that -765G>C polymorphism was significantly associated with susceptibility to CRC in Asian populations.

Keyword

Colorectal cancer; cyclooxygenase-2; polymorphism; meta-analysis

MeSH Terms

Asian Continental Ancestry Group
Case-Control Studies
Colorectal Neoplasms/*genetics
Cyclooxygenase 2/*genetics
Genetic Predisposition to Disease/genetics
Humans
Polymorphism, Genetic/*genetics
Cyclooxygenase 2

Figure

• 

  Fig. 1 Flow chart showing study selection procedure.

• 

  Fig. 2 Meta-analysis of the association between -765G>C polymorphism and susceptibility to colorectal cancer. (A) Dominant model. (B) GC vs. GG. CI, confidence interval.

• 

  Fig. 3 Subgroup analysis of -765G>C polymorphism by ethnicity. (A) dominant model. (B) GC vs. GG. CI, confidence interval.

• 

  Fig. 4 Meta-analysis of the association between COX-2 polymorphism and susceptibility to colorectal cancer in the dominant model. (A) -1195G>A. (B) 8473T>C. (C) Val511Ala. CI, confidence interval.

• 

  Fig. 5 Begg's funnel plot for publication bias. Each point represents a separate study for the indicated association. Log [OR], natural logarithm of OR. Horizontal line, mean effect size. (A) -765G>C. (B) -1195G>A. (C) 8473T>C. (D) Val511Ala. OR, odds ratio.

Reference

1. Hutter CM, Chang-Claude J, Slattery ML, Pflugeisen BM, Lin Y, Duggan D, et al. Characterization of gene-environment interactions for colorectal cancer susceptibility loci. Cancer Res. 2012; 72:2036–2044.

2. Trifan OC, Hla T. Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis. J Cell Mol Med. 2003; 7:207–222.

3. Gately S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev. 2000; 19:19–27.

4. Oshima H, Oshima M. The inflammatory network in the gastrointestinal tumor microenvironment: lessons from mouse models. J Gastroenterol. 2012; 47:97–106.

5. van Rees BP, Ristimäki A. Cyclooxygenase-2 in carcinogenesis of the gastrointestinal tract. Scand J Gastroenterol. 2001; 36:897–903.

6. Gasparini G, Longo R, Sarmiento R, Morabito A. Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? Lancet Oncol. 2003; 4:605–615.

7. Fritsche E, Baek SJ, King LM, Zeldin DC, Eling TE, Bell DA. Functional characterization of cyclooxygenase-2 polymorphisms. J Pharmacol Exp Ther. 2001; 299:468–476.

8. Wiesner GL, Platzer P, Buxbaum S, Lewis S, MacMillen M, Olechnowicz J, et al. Testing for colon neoplasia susceptibility variants at the human COX2 locus. J Natl Cancer Inst. 2001; 93:635–639.

9. Hamajima N, Takezaki T, Matsuo K, Saito T, Inoue M, Hirai T, et al. Genotype Frequencies of Cyclooxygenease 2 (COX2) Rare Polymorphisms for Japanese with and without Colorectal Cancer. Asian Pac J Cancer Prev. 2001; 2:57–62.

10. Cox DG, Pontes C, Guino E, Navarro M, Osorio A, Canzian F, et al. Polymorphisms in prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) and risk of colorectal cancer. Br J Cancer. 2004; 91:339–343.

11. Koh WP, Yuan JM, van den, Lee HP, Yu MC. Interaction between cyclooxygenase-2 gene polymorphism and dietary n-6 polyunsaturated fatty acids on colon cancer risk: the Singapore Chinese Health Study. Br J Cancer. 2004; 90:1760–1764.

12. Tan W, Wu J, Zhang X, Guo Y, Liu J, Sun T, et al. Associations of functional polymorphisms in cyclooxygenase-2 and platelet 12-lipoxygenase with risk of occurrence and advanced disease status of colorectal cancer. Carcinogenesis. 2007; 28:1197–1201.

13. Xing LL, Wang ZN, Jiang L, Zhang Y, Xu YY, Li J, et al. Cyclooxygenase 2 polymorphism and colorectal cancer: -765G>C variant modifies risk associated with smoking and body mass index. World J Gastroenterol. 2008; 14:1785–1789.

14. Iglesias D, Nejda N, Azcoita MM, Schwartz S Jr, González-Aguilera JJ, Fernández-Peralta AM. Effect of COX2 -765G>C and c.3618A>G polymorphisms on the risk and survival of sporadic colorectal cancer. Cancer Causes Control. 2009; 20:1421–1429.

15. Thompson CL, Plummer SJ, Merkulova A, Cheng I, Tucker TC, Casey G, et al. No association between cyclooxygenase-2 and uridine diphosphate glucuronosyltransferase 1A6 genetic polymorphisms and colon cancer risk. World J Gastroenterol. 2009; 15:2240–2244.

16. Hoff JH, te Morsche RH, Roelofs HM, van der Logt EM, Nagengast FM, Peters WH. COX-2 polymorphisms -765G-->C and -1195A-->G and colorectal cancer risk. World J Gastroenterol. 2009; 15:4561–4565.

17. Andersen V, Ostergaard M, Christensen J, Overvad K, Tjønneland A, Vogel U. Polymorphisms in the xenobiotic transporter Multidrug Resistance 1 (MDR1) and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study. BMC Cancer. 2009; 9:407.

18. Pereira C, Pimentel-Nunes P, Brandão C, Moreira-Dias L, Medeiros R, Dinis-Ribeiro M. COX-2 polymorphisms and colorectal cancer risk: a strategy for chemoprevention. Eur J Gastroenterol Hepatol. 2010; 22:607–613.

19. Daraei A, Salehi R, Mohamadhashem F. PTGS2 (COX2) -765G>C gene polymorphism and risk of sporadic colorectal cancer in Iranian population. Mol Biol Rep. 2012; 39:5219–5224.

20. Siezen CL, Bueno-de-Mesquita HB, Peeters PH, Kram NR, van Doeselaar M, van Kranen HJ. Polymorphisms in the genes involved in the arachidonic acid-pathway, fish consumption and the risk of colorectal cancer. Int J Cancer. 2006; 119:297–303.

21. Lin HJ, Lakkides KM, Keku TO, Reddy ST, Louie AD, Kau IH, et al. Prostaglandin H synthase 2 variant (Val511Ala) in African Americans may reduce the risk for colorectal neoplasia. Cancer Epidemiol Biomarkers Prev. 2002; 11:1305–1315.

22. Goodman JE, Bowman ED, Chanock SJ, Alberg AJ, Harris CC. Arachidonate lipoxygenase (ALOX) and cyclooxygenase (COX) polymorphisms and colon cancer risk. Carcinogenesis. 2004; 25:2467–2472.

23. Sansbury LB, Millikan RC, Schroeder JC, North KE, Moorman PG, Keku TO, et al. COX-2 polymorphism, use of nonsteroidal anti-inflammatory drugs, and risk of colon cancer in African Americans (United States). Cancer Causes Control. 2006; 17:257–266.

24. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997; 127:820–826.

25. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7:177–188.

26. Mantel N, Haenzel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22:719–748.

27. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50:1088–1101.

28. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315:629–634.

29. Wang D, Mann JR, DuBois RN. The role of prostaglandins and other eicosanoids in the gastrointestinal tract. Gastroenterology. 2005; 128:1445–1461.

30. Leahy KM, Koki AT, Masferrer JL. Role of cyclooxygenases in angiogenesis. Curr Med Chem. 2000; 7:1163–1170.

31. Prescott SM, Fitzpatrick FA. Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta. 2000; 1470:M69–M78.

32. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994; 107:1183–1188.

33. Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer. 2001; 1:11–21.

34. Papafili A, Hill MR, Brull DJ, McAnulty RJ, Marshall RP, Humphries SE, et al. Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol. 2002; 22:1631–1636.

35. Dixon DA. Regulation of COX-2 expression in human cancers. Prog Exp Tumor Res. 2003; 37:52–71.

36. Shaw G, Kamen R. A conserved AU sequence from the 3' untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell. 1986; 46:659–667.

37. Gou Q, Liu CH, Ben-Av P, Hla T. Dissociation of basal turnover and cytokine-induced transcript stabilization of the human cyclooxygenase-2 mRNA by mutagenesis of the 3'-untranslated region. Biochem Biophys Res Commun. 1998; 242:508–512.

38. Dixon DA, Kaplan CD, McIntyre TM, Zimmerman GA, Prescott SM. Post-transcriptional control of cyclooxygenase-2 gene expression. The role of the 3'-untranslated region. J Biol Chem. 2000; 275:11750–11757.